Top Page
China Touyun Tech Group
(1332)
China Touyun Tech Group (1332) vs. iShares MSCI Hong Kong ETF (EWH)
China Touyun Tech Group Business Overview & Revenue Model
China Touyun Tech Group Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 159.97M | 198.64M | 315.82M | 283.50M | 206.79M |
| Gross Profit | 72.07M | 56.60M | 120.12M | 107.05M | 84.61M |
| EBITDA | -27.92M | -228.57M | -144.39M | -83.13M | -87.22M |
| Net Income | -88.11M | -268.94M | -198.06M | -72.95M | -171.99M |
Balance Sheet | |||||
| Total Assets | 550.32M | 607.34M | 887.70M | 1.02B | 971.94M |
| Cash, Cash Equivalents and Short-Term Investments | 69.64M | 36.04M | 144.25M | 93.95M | 254.40M |
| Total Debt | 384.59M | 384.91M | 395.01M | 317.37M | 222.62M |
| Total Liabilities | 590.96M | 586.27M | 604.19M | 537.68M | 415.57M |
| Stockholders Equity | -83.20M | -848.00K | 263.96M | 469.92M | 488.04M |
Cash Flow | |||||
| Free Cash Flow | -53.54M | -13.49M | -39.30M | -304.60M | -140.86M |
| Operating Cash Flow | -49.87M | 3.65M | -26.37M | -53.81M | -15.35M |
| Investing Cash Flow | -4.66M | -70.95M | -17.25M | -147.74M | -47.87M |
| Financing Cash Flow | 35.74M | -27.68M | 102.63M | 123.17M | 160.47M |
China Touyun Tech Group Technical Analysis
China Touyun Tech Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $10.85B | 15.47 | 5.22% | 1.89% | 3.09% | -26.84% | |
64 Neutral | HK$822.74M | 44.56 | 17.56% | 0.65% | -3.27% | -16.88% | |
56 Neutral | HK$1.20B | 416.67 | -3.49% | 2.00% | 4.56% | -186.08% | |
54 Neutral | HK$1.75B | 75.78 | 1.47% | 1.39% | -47.79% | -78.74% | |
52 Neutral | HK$362.93M | 21.50 | -2.27% | 1.86% | -1.96% | -45.69% | |
39 Underperform | HK$238.51M | ― | -335.55% | ― | -19.47% | 67.26% | |
38 Underperform | HK$10.40M | ― | ― | 11.10% | 74.59% |
China Touyun Tech Group Corporate Events
Touyun Biotech Group Limited has announced the composition of its board of directors along with the roles and functions of each member. The announcement details the executive, non-executive, and independent non-executive directors, as well as the membership of the audit, nomination, and remuneration committees. This update provides clarity on the governance structure of the company, which can impact its strategic direction and stakeholder confidence.
Touyun Biotech Group Limited, a company incorporated in Bermuda, has announced a change in the composition of its Nomination Committee. Mr. Cheung Wing Ping, previously a member of the committee, has been appointed as its chairman, replacing Mr. Wang Liang. These changes, effective from July 4, 2025, aim to bring new leadership to the committee, potentially impacting the company’s governance and strategic direction.
Touyun Biotech Group Limited has announced a series of strategic measures to address its liquidity challenges and improve its financial position, as outlined in its 2024 Annual Report. The company is actively launching new health products to expand its market presence and has secured financial support through loans and shareholder agreements to defer debt repayments. Additionally, the company is exploring the sale of non-core assets to bolster working capital, with recent disposals expected to yield significant gains.
China Touyun Tech Group has revised the terms of reference for its Nomination Committee, which is responsible for appointing and managing directors. The committee will consist of at least three members, with a majority being independent non-executive directors, and meetings will be held at least once a year. This move is likely aimed at strengthening governance and ensuring diverse representation within the company’s leadership structure.
Touyun Biotech Group Limited, a company incorporated in Bermuda, announced the results of its Annual General Meeting (AGM) and Special General Meeting (SGM) held on June 13, 2025. The announcement clarified that no participants indicated an intention to abstain from or oppose any resolutions during these meetings. This supplemental information ensures transparency and confirms that all previously disclosed details remain unchanged.
Touyun Biotech Group Limited held a Special General Meeting on June 13, 2025, where a resolution was passed to approve the Disposal Agreement. This agreement involves the sale of 70% of the shares of a target company for RMB13,000,000. The resolution was overwhelmingly supported, with 99.99% of votes in favor, indicating strong shareholder backing for the transaction.
Touyun Biotech Group Limited has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The company has also detailed the membership of its three board committees: Audit, Nomination, and Remuneration, highlighting the roles of each director within these committees. This announcement provides clarity on the governance structure of the company, which is crucial for stakeholders to understand the leadership dynamics and decision-making processes within Touyun Biotech Group Limited.
Touyun Biotech Group Limited, a company incorporated in Bermuda, held its Annual General Meeting (AGM) on June 13, 2025. During the AGM, all proposed resolutions, except for two withdrawn due to the retirement of directors, were approved by shareholders. These resolutions included the re-election of directors, approval of financial statements, and authorization of board actions regarding share management and auditor appointments. The successful passing of these resolutions ensures the continuity of the company’s governance and operational strategies.
Touyun Biotech Group Limited has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The announcement also details the membership of the three key board committees: Audit, Nomination, and Remuneration. This update is significant as it provides clarity on the governance structure of the company, potentially impacting its strategic direction and decision-making processes.
Touyun Biotech Group Limited announced the retirement of directors Mr. Jia Wenjie and Mr. Hu Guohua, effective from the annual general meeting on June 13, 2026. Their retirement results in the withdrawal of resolutions for their re-election at the meeting. Additionally, there is a change in the composition of the board committee, with Ms. Tian Yuze being appointed to the nomination committee, replacing Mr. To Shing Chuen.
Touyun Biotech Group Limited has announced a special general meeting to discuss the approval of a Disposal Agreement. This agreement involves the sale of 70% of the shares of a target company for RMB13,000,000. The outcome of this meeting could significantly impact the company’s strategic direction and shareholder value.
Touyun Biotech Group Limited has announced its Annual General Meeting scheduled for June 13, 2025, in Hong Kong. Key agenda items include the re-election of several directors, the re-appointment of auditors, and granting the board a mandate to issue new shares, which could impact the company’s capital structure and shareholder value.
China Touyun Tech Group, through its wholly-owned subsidiary, has entered into an agreement to sell its 70% stake in a target company to Renaissance International China Limited for RMB13,000,000. This transaction will result in the target company no longer being a subsidiary of China Touyun Tech Group, and its financial results will not be consolidated into the group’s financial statements. The disposal is considered a major and connected transaction under Hong Kong’s Listing Rules, requiring shareholder approval and compliance with specific reporting and announcement requirements.
Touyun Biotech Group Limited has announced its intention to adopt a new share option scheme while terminating the existing one, which was initially adopted in June 2022. The new scheme aims to align with the amended Chapter 17 of the Listing Rules effective from January 2023, and is designed to attract and retain high-caliber personnel by providing additional incentives and promoting the company’s long-term growth and profitability. The adoption of the new scheme is subject to shareholder approval and regulatory permissions.